Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment.
| Website | https://www.ateapharma.com/ |
| Revenue | $25.3 million |
| Employees | 55 (53 on RocketReach) |
| Founded | 2014 |
| Address | 225 Franklin St Suite, 2100, Boston, Massachusetts 02110, US |
| Technologies |
JavaScript
,
HTML
,
PHP
+25 more
(view full list)
|
| Industry | Biotechnology Research, Drug Discovery, Pharmaceuticals |
| Keywords | Antiviral Treatment, Clinical Stage Biopharmaceutical, Pharmaceutical Research, Drug Development, Biopharmaceutical, Unmet Medical Needs, Viral Infections, Rna Therapeutics, Treatment Development, New Medicines, Therapeutic Solutions, Pharmaceutical, Viral Diseases, Clinical Trials, Medicine, Healthcare |
| Competitors | Roche, Pfizer, Amgen, Bristol Myers Squibb, Novartis, Gilead Sciences, AbbVie, Vertex Pharmaceuticals, Regeneron, Sobi - Swedish Orphan Biovitrum AB (publ) +43 more (view full list) |
Looking for a particular Atea Pharmaceuticals, Inc employee's phone or email?
The Atea Pharmaceuticals, Inc annual revenue was $25.3 million in 2026.
John Vavricka is the Chief Commercial Officer of Atea Pharmaceuticals, Inc.
53 people are employed at Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc is based in Boston, Massachusetts.